Novel molecular evidence related to covid-19 in patients with diabetes mellitus

Yu Huang Liao, Jing Quan Zheng, Cai Mei Zheng, Kuo Cheng Lu, You Chen Chao

Research output: Contribution to journalReview articlepeer-review

21 Citations (Scopus)


Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has rapidly evolved into a global pandemic. The hyperglycemia in patients with diabetes mellitus (DM) substantially compromises their innate immune system. SARS-CoV-2 uses human angiotensin-converting enzyme 2 (ACE2) receptors to enter the affected cell. Uncontrolled hyperglycemia-induced glycosylation of ACE2 and the S protein of SARS-CoV-2 could facilitate the binding of S protein to ACE2, enabling viral entry. Downregulation of ACE2 activity secondary to SARS-CoV-2 infection, with consequent accumulation of angiotensin II and metabolites, eventually leads to poor outcomes. The altered binding of ACE2 with SARS-CoV-2 and the compromised innate immunity of patients with DM increase their susceptibility to COVID-19; COVID-19 induces pancreatic β-cell injury and poor glycemic control, which further compromises the immune response and aggravates hyperglycemia and COVID-19 progression, forming a vicious cycle. Sequential cleavage of viral S protein by furin and transmembrane serine protease 2 (TMPRSS2) triggers viral entry to release the viral genome into the target cell. Hence, TMPRSS2 and furin are possible drug targets. As type 1 DM exhibits a Th1-driven autoimmune process, the relatively lower mortality of COVID-19 in type 1 DM compared to type 2 DM might be attributed to an imbalance between Th1 and Th2 immunity. The anti-inflammatory effects of dipeptidyl peptidase-4 inhibitor may benefit patients with DM and COVID-19. The potential protective effects of sodium–glucose cotransporter-2 inhibitor (SGLT2i), including reduction in lactate level, prevention of lowering of cytosolic pH and reduction in pro-inflammatory cytokine levels may justify the provision of SGLT2i to patients with DM and mild or asymptomatic COVID-19. For patients with DM and COVID-19 who require hospitalization, insulin-based treatment is recommended with cessation of metformin and SGLT2i. Further evidence from randomized or case–control clinical trials is necessary to elucidate the effectiveness and pitfalls of different types of medication for DM.

Original languageEnglish
Article number3962
Pages (from-to)1-15
Number of pages15
JournalJournal of Clinical Medicine
Issue number12
Publication statusPublished - Dec 2020


  • Angiotensin-converting enzyme 2
  • Coronavirus disease 2019
  • Diabetes mellitus
  • Hyperglycemia
  • Innate immunity
  • Renin–angiotensin–aldosterone system
  • Severe acute respiratory syndrome coronavirus 2

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Novel molecular evidence related to covid-19 in patients with diabetes mellitus'. Together they form a unique fingerprint.

Cite this